New insider activity at Ligand Pharma ( (LGND) ) has taken place on September 24, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Jason Aryeh recently sold 10,000 shares of Ligand Pharma stock, amounting to a total transaction value of $1,708,041.
Recent Updates on LGND stock
Ligand Pharmaceuticals has recently seen several analysts raise their price targets due to strategic financial moves and positive market sentiment. The company amended its Credit Agreement to extend the maturity date and adjusted its minimum consolidated EBITDA covenant, which is expected to ensure liquidity and financial stability. This move, along with a successful $460 million convertible bond offering, has increased confidence in Ligand’s financial health and strategic initiatives. Analysts have noted that the capital raise and bond offering provide the company with more flexibility for royalty monetization and project finance efforts. Despite these positive developments, some concerns remain regarding declining revenue and valuation metrics, such as a negative P/E ratio, which temper the overall outlook.
Spark’s Take on LGND Stock
According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.
Ligand Pharma’s strong earnings call performance and technical analysis indicators are the most significant factors driving the stock score. The company’s strategic investments and increased financial guidance highlight its growth potential. However, financial performance and valuation concerns, such as declining revenue and a negative P/E ratio, present risks that temper the overall score.
To see Spark’s full report on LGND stock, click here.
More about Ligand Pharma
YTD Price Performance: 57.40%
Average Trading Volume: 240,291
Technical Sentiment Signal: Buy
Current Market Cap: $3.35B